Wave Life Sciences .(WVE) GlobeNewswire· Globenewswire·2025-01-13 14:00Core Insights - Wave Life Sciences Ltd. is advancing its RNA medicines platform with significant milestones expected in 2025, focusing on clinical programs for Duchenne Muscular Dystrophy (DMD), Huntington's Disease (HD), Alpha-1 Antitrypsin Deficiency (AATD), and obesity treatments [1][2][11] Clinical Programs - The company has submitted Clinical Trial Applications (CTAs) for the Phase 1 INLIGHT clinical trial of WVE-007, targeting obesity through a novel GalNAc-siRNA approach, with proof-of-concept data anticipated in 2025 [1][3] - WVE-006 has shown promising proof-of-mechanism data in AATD, with a mean total AAT protein increase to 10.8 micromolar, meeting regulatory approval levels for AAT augmentation therapies [7][8] - The FORWARD-53 trial for WVE-N531 in DMD is ongoing, with interim results showing a mean muscle content-adjusted dystrophin expression of 9.0%, and 48-week data expected in Q1 2025 [7][8] - WVE-003, an allele-selective treatment for HD, has demonstrated a reduction in mutant huntingtin protein and preservation of healthy huntingtin, with plans for a registrational Phase 2/3 study [8][13] Pipeline and Future Plans - The company is expanding its GalNAc-AIMer pipeline and plans to share multidose data for WVE-006 in 2025, along with new preclinical data from hepatic and extra-hepatic RNA editing programs [4][7] - Wave expects to initiate clinical development of additional RNA editing programs, including PNPLA3, LDLR, and APOB, in 2026 [7] - The company is well-capitalized, with a cash runway expected to last into 2027, allowing for continued investment in its clinical programs [9] Upcoming Events - The CEO of Wave Life Sciences is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, highlighting the company's advancements and future strategies [10]